Therapeutic goods streamlining welcomed

Update on NSAIDs: risks and harms
Australia can streamline the regulation of therapeutic goods by removing duplicative and inefficient processes without undermining the safety and quality of medicines, the GBMA says following the Government's response to the Sansom Review.Many of the 32 recommendations of the Expert Review of Medicines and Medical Device Regulation would improve regulatory efficiency and deliver more timely

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Forum: Polypharmacy and deprescribing
Next Jane Halton resigns, thanked by stakeholders